U.S.-UK Pharmaceutical Trade Deal Secures Tariff-Free Access

Britain has successfully negotiated a U.S.-UK pharmaceutical trade deal, granting tariff-free export access for UK-manufactured medicines to the American market in exchange for increased pricing on new U.S. drugs.

This agreement is part of a larger trade accord established last year, promising no tariffs on British pharmaceutical exports for a minimum duration of three years.

Trade Secretary Peter Kyle described it as a testament to the strong economic bond between the nations, highlighting its support for Britain's leading pharmaceutical industry and its protection of skilled employment. Pharmaceuticals constitute a significant portion of UK's exports to the U.S.